NCT05426174View on ClinicalTrials.gov

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

PHASE1CompletedINTERVENTIONAL
Enrollment

233

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

January 3, 2024

Study Completion Date

January 3, 2024

Conditions
Influenza ImmunizationHealthy Volunteers
Interventions
BIOLOGICAL

mRNA NA vaccine

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

BIOLOGICAL

High Dose Quadrivalent Influenza Vaccine

Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Trial Locations (6)

35802

AES - DRS - Optimal Research_Site 8400007, Huntsville

45236

Synexus Clinical Research_Site 8400003, Cincinnati

85020

Central Phoenix Medical Clinic, LLC_Site: 8400010, Phoenix

92108

Optimal Research San Diego, LLC_Site: 8400009, San Diego

32934-8172

AES - DRS - Optimal Research_Site 8400002, Melbourne

61614-4885

AES - DRS - Optimal Research_Site 8400001, Peoria

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY